Report of the task force on designing clinical trials in early (predementia) AD

• Published in: Neurology Vol. 76; no. 3; pp. 280 - 286
• Main Authors: AISEN, P. S, ANDRIEU, S, HENDRIX, S. B, GRUNDMAN, M, SCHNEIDER, L. S, SCHINDLER, R. J, SALMON, E, POTTER, W. Z, THOMAS, R. G, SALMON, D, DONOHUE, M, BEDNAR, M. M, SAMPAIO, C, TOUCHON, J, VELLAS, B, CARRILLO, M, KHACHATURIAN, Z. S, DUBOIS, B, FELDMAN, H. H, PETERSEN, Rc, SIEMERS, E, DOODY, R. S
• Format: Journal Article Web Resource
• Language: English
• Published: Hagerstown, MD Lippincott Williams & Wilkins 18-01-2011
• Subjects: Advisory Committees; alzheimer; Alzheimer Disease - blood; Alzheimer Disease - diagnosis; Alzheimer Disease - diagnostic imaging; Alzheimer Disease - drug therapy; Alzheimer Disease - pathology; Amyloidogenic Proteins - blood; Biological and medical sciences; Biomarkers - blood; Clinical Trials as Topic - methods; Cognition - drug effects; Consensus; design; Disease Progression; Drug Industry; Early Diagnosis; Europe; Human health sciences; Humans; Indans - therapeutic use; International Cooperation; Medical sciences; Multiple sclerosis and variants. Guillain barré syndrome and other inflammatory polyneuropathies. Leukoencephalitis; Neurologie; Neurology; Nootropic Agents - therapeutic use; Outcome Assessment (Health Care); Patient Selection; Piperidines - therapeutic use; Positron-Emission Tomography; Research Design; Sciences de la santé humaine; Treatment Outcome; trials; United States; United States Food and Drug Administration; Views and Reviews; Vitamin E - therapeutic use; Force; Clinical trial; Nervous system diseases
• ISSN: 0028-3878; 1526-632X; 1526-632X
• DOI: 10.1212/wnl.0b013e318207b1b9

A large number of promising candidate disease-modifying treatments for Alzheimer disease (AD) continue to advance into phase II and phase III testing. However, most completed trials have failed to demonstrate efficacy, and there is growing concern that methodologic difficulties may contribute to these clinical trial failures. The optimal time to intervene with such treatments is probably in the years prior to the onset of dementia, before the neuropathology has progressed to the advanced stage corresponding to clinical dementia.
An international task force of individuals from academia, industry, nonprofit foundations, and regulatory agencies was convened to discuss optimal trial design in early (predementia) AD.
General consensus was reached on key principles involving the scope of the AD diagnosis, the selection of subjects for trials, outcome measures, and analytical methods.
A consensus has been achieved in support of the testing of candidate treatments in the early (predementia) AD population.